众生药业预计2025年净利2.6亿元至3.1亿元，同比扭亏

Core Viewpoint - Zhongsheng Pharmaceutical (002317) is expected to achieve a net profit attributable to shareholders of 260 million to 310 million yuan in 2025, representing a year-on-year growth of 186.91% to 203.62%, marking a turnaround from losses [1] Group 1: Financial Performance - The company anticipates a significant increase in net profit for 2025, with projections indicating a range of 260 million to 310 million yuan [1] - This expected profit growth represents a substantial improvement compared to the previous year, indicating a turnaround from losses [1] Group 2: Strategic Focus - Zhongsheng Pharmaceutical is concentrating resources on the research and development of innovative drugs in the fields of metabolic diseases and respiratory diseases [1] - The company has successfully launched two innovative drugs, Lai Ru Te Wei tablets and Ang La Di Wei tablets, which are expected to be key growth drivers for future performance [1]